home / stock / capr / capr news

CAPR News and Press, Capricor Therapeutics Inc. From 06/13/23

Stock Information
Company Name: Capricor Therapeutics Inc.
Stock Symbol: CAPR
Market: NASDAQ
Website: capricor.com
Menu
CAPR CAPR Quote CAPR Short CAPR News CAPR Articles CAPR Message Board
Get CAPR Alerts

News, Short Squeeze, Breakout and More Instantly...
CAPR - Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company ...
CAPR - Capricor to meet with FDA in early Q3 to discuss CAP-1002 application

2023-06-07 12:56:27 ET Capricor Therapeutics ( NASDAQ: CAPR ) said that it plans to meet with the US Food and Drug Administration in early Q3 to discuss its ongoing Phase 3 study and submission of a Biologics License Application for its lead product CAP-1002 for the treatment of Duc...

CAPR - Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

SAN DIEGO, June 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced an upcoming Type-...

CAPR - Capricor Therapeutics, Inc. (CAPR) Q1 2023 Earnings Call Transcript

2023-05-11 17:55:21 ET Capricor Therapeutics, Inc. (CAPR) Q1 2023 Earnings Conference Call May 11, 2023, 04:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Aydin Huseynov - Ladenburg Presentation ...
CAPR - Capricor Therapeutics GAAP EPS of -$0.31 beats by $0.01, revenue of $2.98M beats by $2.48M

2023-05-11 16:03:01 ET Capricor Therapeutics press release ( NASDAQ: CAPR ): Q1 GAAP EPS of -$0.31 beats by $0.01 . Revenue of $2.98M beats by $2.48M . For further details see: Capricor Therapeutics GAAP EPS of -$0.31 beats by $0.01, revenue of $2.98M bea...

CAPR - Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); On Track to Report Interim Analysis in Fourth Quarter of 2023- -Plan to Present 24-Month HOPE-2 Open Label Extension Data in Second Quarter of 2023- -To H...

CAPR - Notable earnings after Thursday's close

2023-05-10 17:35:55 ET Major earnings expected after the bell on Thursday include: Petroleo Brasilerio SA Petrobars ( PBR ) Zomedica Corp. ( ZOM ) Asensus Surgical ( ASXC ) IAMGOLD Corporation ( IAG ) IonQ ( IONQ ) For further details see: ...
CAPR - Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results...

CAPR - Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX(TM) Platform

SAN DIEGO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today the publ...

CAPR - Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company...
Previous 10 Next 10